Clinical trial
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma…
NCT00458601 · Celldex Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00458601 |
|---|---|
| Title | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme |
| Official title | A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
| Acronym | ACT III |
| Lead sponsor | Celldex Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Glioma |
| Intervention type | Drug |
| Interventions | CDX-110 with GM-CSF, Temozolomide |
| Enrollment | 82 |
| Start date | Aug 1, 2007 |
| Primary completion | Nov 1, 2010 |
| Completion | May 1, 2016 |
| First posted | Apr 11, 2007 |
| Last update posted | Jan 16, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: